Challenges and optimisation strategies for nuclear medicine and radiopharmacy in a crisis such as the COVID-19 pandemic and Brexit

The coronavirus pandemic (COVID-19) caused significant disruption to healthcare all over the world and interrupted patient care and service delivery. Limited access to healthcare, primarily to imaging services caused by cancellations and disruption to outpatient services due to extended lockdowns and travel restrictions, meant that the impact on patient care went beyond a diagnostic test. Additionally, patients often had increased waiting times for their diagnostic imaging tests due to new restrictions on patient throughput, infection control procedures and workforce pressures

The content on this page is provided by the individuals concerned and does not represent the views or opinions of RAD Magazine.

Stay up to date with
RAD Magazine

Sign up for our newsletter.

We care about your data. Read our privacy policy.